Evogene (NASDAQ:EVGN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Evogene (NASDAQ:EVGNFree Report) in a research report released on Saturday morning. The firm issued a sell rating on the biotechnology company’s stock.

Evogene Trading Up 1.3 %

Shares of Evogene stock opened at $0.66 on Friday. The business’s 50-day moving average price is $0.73 and its 200-day moving average price is $0.76. Evogene has a 12 month low of $0.45 and a 12 month high of $1.44.

Evogene (NASDAQ:EVGNGet Free Report) last announced its quarterly earnings data on Thursday, March 7th. The biotechnology company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.01. The firm had revenue of $0.58 million for the quarter, compared to analyst estimates of $1.73 million. Evogene had a negative return on equity of 76.93% and a negative net margin of 423.39%. During the same period in the prior year, the company earned ($0.07) EPS.

Hedge Funds Weigh In On Evogene

An institutional investor recently raised its position in Evogene stock. BNP Paribas Financial Markets increased its stake in shares of Evogene Ltd. (NASDAQ:EVGNFree Report) by 30.8% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,400 shares of the biotechnology company’s stock after acquiring an additional 21,500 shares during the quarter. BNP Paribas Financial Markets owned approximately 0.22% of Evogene worth $69,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

(Get Free Report)

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.

Featured Stories

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.